Stock Details
TAK is Takeda Pharmaceutical Company Limited's stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 16.85$. Average daily volumn in 3 months 2.06M. Market cap 52.78B



Stock symbol : TAK. Exchange : NYSE. Currency : USD
Lastest price : 16.50$. Total volume : 3.08M. Market state PRE
Click reload if you want to check the lastest price on market!!!

Takeda Pharmaceutical Company Limited (TAK)
Last Price
16.50$
Change
-0.43
Volume
3.08M

Previous Close16.93
Open16.82
Day Range16.40-16.84
Bid0.00 x 2.9k
Ask0.00 x 800
Volume3.08M
Average Volume2.06M
Market Cap52.78B
BetaN/A
52 Week Range15.30-19.97
Trailing P/E11.52
Foward P/E22.00
Dividend (Yield %)5.07%
Ex-Dividend Date2021-03-30



Financial Details


According to Takeda Pharmaceutical Company Limited's financial reports the company's revenue in 2021 were 3.2T an increase(0%) over the years 2020 revenue that were of 3.29T. In 2021 the company's total earnings were 376B while total earnings in 2020 were 44.24B( +754.55%).


Loading ...



Organization

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical and biopharmaceutical company. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US $19.299 billion in revenue during the 2018 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent s... ubsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and President of Takeda.

Takeda Pharmaceutical Company Limited_logo

Market Cap:
52.78B
Revenue:
3.2T
Total Assets:
12.91T
Total Cash:
966.22B


News about "Takeda Pharmaceutical Company Limited"

Where Do Hedge Funds Stand On Takeda Pharmaceutical Company Limited (TAK)?_image

Where Do Hedge Funds Stand On Takeda Pharmaceutical Company Limited (TAK)?

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds’ and ...

Source from : YAHOO!Finance - 10 days ago


Takeda Pharmaceutical Company Limited [TAK] is -5.88% lower this YTD. Is it still time to buy?_image

Takeda Pharmaceutical Company Limited [TAK] is -5.88% lower this YTD. Is it still time to buy?

TAK] gained 2.15% or 0.36 points to close at $17.13 with a heavy trading volume of 2457253 shares. The company report on July 28, 2021 that U.S. Food and Drug Administration Grants Breakthrough ...

Source from : dbtnews - 3 days ago


Check This Takeda Pharmaceutical Company Limited (NYSE: TAK) Analysis Before You Invest

Takeda Pharmaceutical Company Limited (NYSE:TAK) traded at $17.08 at last check on Wednesday, July 28, made an upward move of 1.82% on its previous day’s price. Looking at the stock we see that its ...

Source from : stocksregister - 4 days ago


Takeda, Frazier Healthcare to launch biopharma company for norovirus vaccine_image

Takeda, Frazier Healthcare to launch biopharma company for norovirus vaccine

Takeda has granted licence to HilleVax for the exclusive development and commercialization rights to its norovirus vaccine candidate HIL-214 outside of Japan ...

Source from : Mint - 2 days ago


Takeda Pharmaceutical Company Limited (TAK) and the Battle of Fundamentals vs. Technicals_image

Takeda Pharmaceutical Company Limited (TAK) and the Battle of Fundamentals vs. Technicals

Takeda Pharmaceutical Company Limited (NYSE:TAK) went down by -0.94% from its latest closing price compared to the recent 1-year high of $19.97. The company’s stock price has collected -2.38% of loss ...

Source from : newsheater - 1 month ago


Analysts Mean recommendation for Takeda Pharmaceutical Company Limited (TAK) was 2.30: Is this the key time?

Takeda Pharmaceutical Company Limited (TAK) is priced at $17.13 after the most recent trading session. At the very opening of the session, the stock price was $16.84 and reached a high price of $17.20 ...

Source from : investchronicle - 1 month ago


Takeda Pharma Q1 Profit Surges, Maintains FY Outlook - Quick Facts_image

Takeda Pharma Q1 Profit Surges, Maintains FY Outlook - Quick Facts

Japan's Takeda Pharmaceutical Co. Ltd. (TAK) reported Friday that its first-quarter net profit was 200.4 billion yen, a 142.8 percent increase from the prior year. Earnings per share were 128 yen, up ...

Source from : Nasdaq - 3 days ago


Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first quarter of fiscal year 2021 (pe ...

Source from : Business Wire - 3 days ago


Takeda Pharmaceutical Co Ltd (TAK): Price Now Near $16.83; Daily Chart Shows Downtrend on 100 Day Basis_image

Takeda Pharmaceutical Co Ltd (TAK): Price Now Near $16.83; Daily Chart Shows Downtrend on 100 Day Basis

TAK ranks 128th in terms of today’s price percentage change out of Pharmaceutical Products stocks. Currently, TAK’s price is down $-0.03 (-0.15%) from the day prior. It’s been a feast for bears ...

Source from : ETF Daily News - 10 days ago


The curious case of Eohilia: Takeda drug hit with mysterious FDA delay as company leans on launches for growth_image

The curious case of Eohilia: Takeda drug hit with mysterious FDA delay as company leans on launches for growth

Takeda CEO Christophe Weber has been labeling 2021 as an “inflection year” for the Japanese pharma as it looks to advance its late-stage pipeline and introduce several new drugs. But at least one drug ...

Source from : FiercePharma - 3 days ago


Takeda expansion is latest coup for Conejo Valley pharma industry_image

Takeda expansion is latest coup for Conejo Valley pharma industry

Takeda Pharmaceuticals, a Japanese company with major operations in the Conejo Valley, will expand its facility in Thousand Oaks, investing $126 million to build out the manufacturing operations to ...

Source from : Pacbiztimes.com - 10 days ago


Takeda Pharmaceutical Co. Ltd. ADR

1 Day TAK 0.78% DJIA 0.20% S&P 500 0.51% Health Care/Life Sciences 1.30% Christophe Weber President, CEO & Representative Director Takeda Pharmaceutical Co., Ltd. Constantine Saroukos Chief ...

Source from : Wall Street Journal - 1 month ago


Oral Anti Diabetic Drug Market Revenue To Witness Humongous Elevation By 2030| Takeda Pharmaceutical Company Ltd, Pfizer Inc

The “International Oral Anti Diabetic Drug Market” presents by Marketresearch.biz which is a profound evaluation ...

Source from : MarketWatch - 11 days ago


Takeda Pharmaceuticals Marks its 240th Founding Anniversary

any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") regarding this release. This press release (including ...

Source from : Business Insider - 1 month ago


Takeda Pharmaceutical Company Limited (TKD.VI)

OSAKA, Japan, July 10, 2021--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced results from two final analyses from the Phase 3 HELP (Hereditary Angioedema Long-term ...

Source from : Yahoo Finance - 22 days ago


Takeda Pharmaceutical Company Limited (4502.T)

2021--Takeda Pharmaceutical Company Limited ("Takeda") (TOKYO:4502) (NYSE:TAK) today announced that it has filed its Corporate Governance Report with the Tokyo Stock Exchange ("TSE") in accordance ...

Source from : Yahoo Finance - 23 days ago


Global Stress Management Supplements Market 2021 Industry Survey Research Report 2026 – Top Player as Ion Labs Inc, Takeda Pharmaceutical Co. Ltd

Ion Labs Inc, Takeda Pharmaceutical Co. Ltd, Teva Pharmaceutical Industries ... trends in the forthcoming years. Competitive companies and manufacturers in the global Stress Management Supplements ...

Source from : Digital Journal - 27 days ago


Incredible Growth of Bortezomib Market – SWOT Analysis by Key Factors from 2021-2028 |Gls Pharma Ltd, Natco Pharma Limited, Takeda,

The worldwide Bortezomib market size is projected to make from USD XX 2021 to USD XX by 2028, at a Compound Annual Growth Rate (CAGR) of XX during the gauge time frame. The global Bortezomib market is ...

Source from : manometcurrent.com - 5 days ago


Takeda Pharmaceutical Company Limited (4502.T)

OSAKA, Japan, June 29, 2021--Takeda Pharmaceutical Company Limited ("Takeda") (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, ...

Source from : Yahoo Finance - 1 month ago


Takeda Pharmaceutical Co Ltd

When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.

Source from : Bloomberg - 20 days ago


Takeda Pharmaceutical Co Ltd TKD

There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ...

Source from : Morningstar%2c Inc. - 1 month ago


Daily High to Daily Low: Is It Safe to Buy Takeda Pharmaceutical Company Limited (TAK)?

Takeda Pharmaceutical Company Limited (NYSE:TAK) went up by 2.15% from its latest closing price compared to the recent 1-year high of $19.97. The company’s stock price has collected 1.66% of gains in ...

Source from : newsheater - 6 month ago


Takeda Pharmaceutical Co Ltd

(([email protected];)). Novadiscovery Entered Into A New Collaboration With Takeda Pharmaceutical Company Limited March 26 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T ...

Source from : Reuters - 11 month ago


Takeda Pharmaceutical Co. Ltd.

Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...

Source from : Wall Street Journal - 11 month ago


Takeda Pharmaceutical Co. Ltd.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Source from : Barron's - 8 month ago


Takeda Pharmaceutical Company Limited (TKPHF)

*Close price adjusted for splits.**Adjusted close price adjusted for both dividends and splits. Loading more data ...

Source from : Yahoo Finance - 3 month ago


Takeda Pharmaceutical Co - ADR

Takeda Pharmaceutical Co., Ltd. engages in the research and development ... and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Source from : U.S. News & World Report - 1 year ago


Takeda To Record Provision Of 63 Bln Yen On Irish Tax Issue_image

Takeda To Record Provision Of 63 Bln Yen On Irish Tax Issue

Takeda Pharmaceutical Company Limited (TKPHF.PK, TAK) said it will record a provision of about 63 billion yen in its financial statements for the first quarter to reflect a decision by the Irish Tax ...

Source from : Nasdaq - 12 hours ago


Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie_image

Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the receipt of a decision by the Irish Tax Appeals Commission on July 30, 2021 (IST) to uphold the Irish Revenue ...

Source from : Yahoo - 15 hours ago


BRIEF-Takeda Says Receives Decision By Irish Tax Appeals Commission Relating To Tax Assessment On Break Fee Shire Received From Abbvie

TAKEDA RECEIVES DECISION BY THE IRISH TAX APPEALS COMMISSION RELATING TO TAX ASSESSMENT ON BREAK FEE SHIRE RECEIVED FROM ABBVIE * TAKEDA PHARMACEUTICAL CO LTD - INTENDS TO CHALLENGE THIS OUTCOME THROU ...

Source from : Reuters on MSN.com - 15 hours ago


Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate_image

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate

Takeda Will Focus its Efforts on Dengue, Zika and Pandemic VaccinesDubai, United Arab Emirates, July 30, 2021 (GLOBE NEWSWIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) and ...

Source from : YAHOO!Finance - 3 days ago


Takeda to record 63 billion yen provision, update Q1 results on Irish tax issue_image

Takeda to record 63 billion yen provision, update Q1 results on Irish tax issue

Takeda Pharmaceutical Co said on Monday it will record a provision of about 63 billion yen ($574.56 million) in its financial statements for the first quarter to reflect a decision by Ireland's tax ...

Source from : Reuters - 14 hours ago


Takeda Announces the Submission of Its Corporate Governance Report to the Tokyo Stock Exchange

Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502) (NYSE:TAK) today announced that it has filed its Corporate Governance Report with the To ...

Source from : Business Wire - 14 days ago


Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020

Takeda Pharmaceutical Company Limited ("Takeda") (NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2021 (the "Annual Report") with the ...

Source from : Benzinga.com - 1 month ago


Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020

Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2021 (the “Annual ...

Source from : The Register-Herald - 1 month ago


The Globe and Mail

Takeda Pharmaceutical Company Limited ("Takeda") (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2021 (the "Annual Report ...

Source from : The Globe and Mail - 1 month ago


Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020

Takeda Pharmaceutical Company Limited (“Takeda”) (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2021 ...

Source from : Stockhouse - 1 month ago


Takeda eyeing healthy business in China

[Photo/Xinhua] Japanese drugmaker Takeda Pharmaceutical Co Ltd is planning to further accelerate ... China's booming pharmaceutical sector, said a company executive. The company, which aims ...

Source from : China Daily - 20 days ago


Takeda Announces the Publication of Its Annual Report on Form 20-F for FY2020

OSAKA, Japan, June 29, 2021--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited ("Takeda") (TSE:4502/NYSE:TAK) today announced that it has filed its Annual Report on Form 20-F for the fiscal year ...

Source from : Yahoo Finance - 1 month ago


The Globe and Mail

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced the exercise of its option to acquire Maverick Therapeutics, Inc. a private biopharmaceutical company ...

Source from : The Globe and Mail - 4 month ago


Orally Disintegrating Tablet (ODT) Market Size and Growth Prospects 2019 – 2027

The MarketWatch News Department was not involved in the creation of this content. Jul 07, 2021 (Heraldkeepers) -- New ODT advancements address numerous pharmaceutical and patient needs, going from ...

Source from : MarketWatch - 25 days ago


CNDAP Partners with Takeda to Develop New Therapies for Alzheimer's Disease and Related Brain Disorders

SAN FRANSISCO, June 16, 2021 /PRNewswire/ -- Cure Network Dolby Acceleration Partners LLC (CNDAP) and Takeda Pharmaceutical Company Limited ("Takeda") have entered into a research collaboration to ...

Source from : thedailytimes.com - 1 month ago


Crohn?s Disease Therapeutics Market

Higher prevalence of autoimmune disorders, a larger population base requiring effective therapies for diseases such as the Crohn’s disease, and increasing prevalence of inflammatory bowel ...

Source from : openpr.com - 1 month ago


Lack of preparedness on Covid-19 is greatest failure of our collective ecosystem: US scientist

Takeda Pharmaceutical Company Limited, told PTI in an interview. “Covid-19 is the worst health crisis of our generation or the generation before us. It has been a travesty. It’s horrible what ...

Source from : Business Line - 1 month ago